


SMIP004

Cat. No.:	HY-15694		
CAS No.:	143360-00-3		
Molecular Formula:	C ₁₃ H ₁₉ NO		
Molecular Weight:	205.3		
Target:	E1/E2/E3 Enzyme; Apoptosis		
Pathway:	Metabolic Enzyme/Protease; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (487.09 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		4.8709 mL	24.3546 mL	48.7092 mL
	5 mM		0.9742 mL	4.8709 mL	9.7418 mL
	10 mM		0.4871 mL	2.4355 mL	4.8709 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (12.18 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (12.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SMIP004 is a SKP2 E3 ligase inhibitor, which downregulates SKP2 and to stabilise p27. SMIP004 is a cancer cell selective apoptosis inducer of human prostate cancer cells^{[1][2]}.

IC₅₀ & Target

SKP2 E3 ligase^[1]

In Vitro

SMIP004 decreases the levels of positive cell cycle regulators, upregulates cyclin-dependent kinase inhibitors, and results in G1 arrest, inhibition of colony formation in soft agar, and cell death^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in SCID mice^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Exp Clin Cancer Res. 2019 Feb 13;38(1):76.
- Eur J Pharmacol. 2019 Jan 15;843:260-267.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Li C, et al. SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res. 2019 Feb 13;38(1):76.
- [2]. Rico-Bautista E, Zhu W, Kitada S, Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via UPR Signaling. Oncotarget. 2013 Jul 14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA